Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ School of Medicine, New Hyde Park, New York.
Department of Urology, Smith Institute for Urology, Hofstra North Shore LIJ School of Medicine, New Hyde Park, New York.
J Urol. 2016 Apr;195(4 Pt 1):859-64. doi: 10.1016/j.juro.2015.10.132. Epub 2015 Oct 29.
A clinical dilemma surrounds the use of aspirin therapy during laparoscopic partial nephrectomy. Despite reduced cardiac morbidity with perioperative aspirin use, fear of bleeding related complications often prompts discontinuation of therapy before surgery. We evaluate perioperative outcomes among patients continuing aspirin and those in whom treatment is stopped preoperatively.
A total of 430 consecutive cases of laparoscopic partial nephrectomy performed between January 2012 and October 2014 were reviewed. Patients on chronic aspirin therapy were stratified into on aspirin and off aspirin groups based on perioperative status of aspirin use. Primary end points evaluated included estimated intraoperative blood loss and incidence of bleeding related complications, major postoperative complications, and thromboembolic events. Secondary outcomes included operative time, transfusion rate, length of hospital stay, rehospitalization rate and surgical margin status.
Among 101 (23.4%) patients on chronic aspirin therapy, antiplatelet treatment was continued in 17 (16.8%). Bleeding developed in 1 patient in the on aspirin group postoperatively and required angioembolization. Conversely 1 myocardial infarction was observed in the off aspirin cohort. There was no significant difference in the incidence of major postoperative complications, intraoperative blood loss, transfusion rate, length of hospital stay and rehospitalization rate. Operative time was increased with continued aspirin use (181 vs 136 minutes, p=0.01).
Laparoscopic partial nephrectomy is safe and effective in patients on chronic antiplatelet therapy who require perioperative aspirin for cardioprotection. Larger, prospective studies are necessary to discern the true cardiovascular benefit derived from continued aspirin therapy as well as better characterize associated bleeding risk.
在腹腔镜部分肾切除术期间使用阿司匹林治疗存在临床困境。尽管围手术期使用阿司匹林可降低心脏发病率,但由于担心与出血相关的并发症,术前常停止治疗。我们评估了继续使用阿司匹林和术前停止治疗的患者的围手术期结局。
回顾了 2012 年 1 月至 2014 年 10 月期间进行的 430 例连续腹腔镜部分肾切除术病例。根据围手术期阿司匹林使用情况,将接受慢性阿司匹林治疗的患者分为阿司匹林组和非阿司匹林组。主要评估终点包括估计术中失血量和出血相关并发症、主要术后并发症和血栓栓塞事件的发生率。次要结果包括手术时间、输血率、住院时间、再住院率和手术边缘状态。
在 101 例(23.4%)接受慢性阿司匹林治疗的患者中,17 例(16.8%)继续接受抗血小板治疗。阿司匹林组 1 例患者术后出血,需要血管栓塞治疗。相反,非阿司匹林组有 1 例心肌梗死。主要术后并发症、术中失血量、输血率、住院时间和再住院率无显著差异。继续使用阿司匹林会增加手术时间(181 分钟 vs 136 分钟,p=0.01)。
对于需要围手术期阿司匹林进行心脏保护的接受慢性抗血小板治疗的患者,腹腔镜部分肾切除术是安全有效的。需要更大规模的前瞻性研究来确定继续使用阿司匹林治疗带来的真正心血管益处,并更好地描述相关出血风险。